2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P0176A
    PACAP (1-27), human, ovine, rat TFA 99.87%
    PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively.
    PACAP (1-27), human, ovine, rat TFA
  • HY-P1013A
    Deltorphin 2 TFA 99.93%
    Deltorphin 2 TFA is a selective peptide agonist for the δ opioid receptor.
    Deltorphin 2 TFA
  • HY-P1329A
    CTOP TFA 99.84%
    CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity.
    CTOP TFA
  • HY-P1339B
    Orexin B, human acetate 99.68%
    Orexin B, human acetate is the acetate form of Orexin B, human (HY-P1339). Orexin B, human acetate is the agonist for Orexin Receptor, with Ki of 420 nM and 36 nM for OX1 and OX2. Orexin B, human acetate participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine.
    Orexin B, human acetate
  • HY-P1485A
    Substance P(1-7) TFA 2828433-22-1 99.14%
    Substance P(1-7) TFA is a fragment of the neuropeptide, substance P (SP). Substance P(1-7) TFA gives depressor and bradycardic effects when applied to the nucleus tractus solitarius.
    Substance P(1-7) TFA
  • HY-P1754A
    Tetanus toxin (830-843) TFA
    Tetanus toxin (830-843) TFA is a powerful neurotoxin that reaches by retroaxonal transport and transcytosis the cytoplasm ofspinal inhibitory intemeurons and blocks their ability to release neurotransmitters.
    Tetanus toxin (830-843) TFA
  • HY-P3460A
    TDSRCVIGLYHPPLQVY TFA 99.95%
    TDSRCVIGLYHPPLQVY TFA is a disordered control peptide. TDSRCVIGLYHPPLQVY TFA is a peptide containing the same amino acids as LP17 (HY-P3400) but in a different sequence order.
    TDSRCVIGLYHPPLQVY TFA
  • HY-P3870A
    DALDA acetate 99.78%
    DALDA acetate is a potent and highly selective μ-opioid receptor agonist with a Ki of 1.69 nM. DALDA acetate shows antinociceptive and respiratory effects.
    DALDA acetate
  • HY-P4704A
    α-Synuclein (61-95) (human) TFA
    α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
    α-Synuclein (61-95) (human) TFA
  • HY-P5785A
    Heteropodatoxin-2 TFA
    Heteropodatoxin-2 (TFA), a peptides of 30-amino acid, is a heteropodatoxin. Heteropodatoxin-2 blocks Kv4.2 current expressed in Xenopus laevis oocytes in a voltage-dependent manner, with less block at more positive potentials.
    Heteropodatoxin-2 TFA
  • HY-100805S
    D-Glutamic acid-d5 14341-88-9 99.91%
    D-Glutamic acid-d5 is the deuterium labeled D-Glutamic acid. D-glutamic acid, an enantiomer of L- glutamic acid, is widely used in pharmaceuticals and foods.
    D-Glutamic acid-d5
  • HY-101290A
    BMT-090605 hydrochloride 2231664-45-0 98.76%
    BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain.
    BMT-090605 hydrochloride
  • HY-101402A
    Cyclo(his-pro) TFA 936749-56-3 99.13%
    Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone. Cyclo(his-pro) TFA could inhibit NF-κB nuclear accumulation. Cyclo(his-pro) TFA can cross the brain-blood-barrier and affect diverse inflammatory and stress responses.
    Cyclo(his-pro) TFA
  • HY-105252A
    BF 227 845647-80-5 98.88%
    BF 227 is a candidate for an amyloid imaging probe for PET, with a Ki of 4.3 nM for Aβ1-42 fibrils.
    BF 227
  • HY-106901A
    Asoxime dichloride 34433-31-3 ≥98.0%
    Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system.
    Asoxime dichloride
  • HY-107606A
    UBP301 hydrochloride
    UBP301 hydrochloride is a potent and selective antagonist of kainate receptor with IC50 and KD of 164 μM and 5.94 μM, respectively. UBP301 hydrochloride has ～30-fold selectivity of kainate receptor over AMPA receptor. UBP301 hydrochloride is the derivative of willardiine.
    UBP301 hydrochloride
  • HY-107664A
    SR 142948 dihydrochloride ≥98.0%
    SR 142948 dihydrochloride is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC50s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 dihydrochloride antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 dihydrochloride blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 dihydrochloride shows blood-brain permeability and can be used in study of psychiatric disorders.
    SR 142948 dihydrochloride
  • HY-110036A
    GW405833 hydrochloride 1202865-22-2 99.59%
    GW405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB2) agonist. GW405833 has EC50 and Ki values ​​of 0.65 nM and 3.92 nM for CB2, and EC50 and Ki values ​​of 16.1 μM and 4772 nM for CB1. GW405833 hydrochloride also exhibits non-competitive CB1 antagonist, exerting its analgesic effect through a CB1 receptor (rather than CB2) dependent mechanism. GW405833 hydrochloride can significantly inhibit the production of cAMP stimulated by Forskolin (HY-15371). GW405833 hydrochloride inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF).
    GW405833 hydrochloride
  • HY-110121A
    NS3861 216853-59-7 99.78%
    NS3861 is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding Ki values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively.
    NS3861
  • HY-110135A
    NBI-31772 hydrate ≥98.0%
    NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects.
    NBI-31772 hydrate
Cat. No. Product Name / Synonyms Application Reactivity